Early intervention with epoetin beta prevents severe anaemia in patients with solid tumours receiving platinum-based chemotherapy: Results of the NeoPrevent study

Cancer Chemotherapy and Pharmacology

Volumn 59, Issue 1, 2007, Pages 35-42

  De Castro, Javier ^a   Ordóñez, Amalio ^a   Isla, Dolores ^b   Sánchez, Alfredo ^c   Arrivi, Antonio ^d   Manzano, José Luis ^e   Barón, Manuel González ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

^c HOSPITAL PROVINCIAL DE CASTELLÓN   (Spain)

^d HOSPITAL SON LLÀTZER   (Spain)

^e HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

Anaemia; Epoetin beta; Platinum based chemotherapy; Solid tumours

Indexed keywords

CARBOPLATIN; CISPLATIN DERIVATIVE; FERRITIN; HEMOGLOBIN; IRON; OXALIPLATIN; RECOMBINANT ERYTHROPOIETIN;

ADULT; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HEMOGLOBIN DETERMINATION; HUMAN; ISCHEMIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OCCLUSIVE CEREBROVASCULAR DISEASE; PRIORITY JOURNAL; QUALITY OF LIFE; SKIN MANIFESTATION; SOLID TUMOR; STATISTICAL SIGNIFICANCE; VEIN THROMBOSIS;

ACTIVITIES OF DAILY LIVING; ADULT; AGED; AGED, 80 AND OVER; ANEMIA; ANTINEOPLASTIC AGENTS; ERYTHROPOIETIN, RECOMBINANT; FEMALE; FERRITINS; HEMOGLOBINS; HUMANS; IRON; MALE; MIDDLE AGED; NEOPLASMS; ORGANOPLATINUM COMPOUNDS; QUALITY OF LIFE;

EID: 33751295588     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-006-0251-4     Document Type: Article

References (31)

1. Groopman JE, Itri LM (1999) Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst 91:1616-1634
2. Ludwig H, Van Belle S, Barrett-Lee P et al (2004) The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer 40:2293-2306
3. Langer CJ, Choy H, Glaspy JA, Colowick A (2002) Standards of care for anemia management in oncology. Focus on lung cancer. Cancer 95:613-623
4. Cella D (1998) Factors influencing quality of life in cancer patients: anemia and fatigue. Semin Oncol 25(Suppl 7):43-46
5. Caro JJ, Salas M, Ward A, Goss G (2001) Anemia as an independent prognostic factor for survival in patients with cancer: a systematic, quantitative review. Cancer 91:2214-2221
6. MacRae R, Shyr Y, Johnson D, Choy H (2002) Declining hemoglobin during chemoradiotherapy for locally advanced non-small cell lung cancer is significant. Radiother Oncol 64:37-40
7. Albain KS, Crowley JJ, LeBlanc M, Livingston RB (1991) Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience. J Clin Oncol 9:1618-1626
8. Nisman B, Barak V, Hubert A et al (2003) Prognostic factors for survival in metastatic breast cancer during first-line paclitaxel chemotherapy. Anticancer Res 23:1939-1942
9. Dunst J, Kuhnt T, Strauss HG et al (2003) Anemia in cervical cancers: impact on survival, patterns of relapse, and association with hypoxia and angiogenesis. Int J Radiat Oncol Biol Phys 56:778-787
10. Jelkmann W (2004) Molecular biology of erythropoietin. Intern Med 43:649-659
11. Österborg A, Brandberg Y, Molostova V et al (2002) Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin beta, in hematologic malignancies. J Clin Oncol 20:2486-2494
12. Glimelius B, Linne T, Hoffman K et al (1998) Epoetin beta in the treatment of anemia in patients with advanced gastrointestinal cancer. J Clin Oncol 16:434-440
13. Bogdanos J, Karamanolakis D, Milathianakis K et al (2004) Epoetin beta (NeoRecormon®) corrects anaemia in patients with hormone-refractory prostate cancer and bone metastases. Anticancer Res 24:1957-1962
14. Boogaerts M, Coiffier B, Kainz C (2003) Epoetin β QOL working group. Impact of epoetin β on quality of life in patients with malignant disease. Br J Cancer 88:988-995
15. Kunikane H, Watanabe K, Fukuoka M et al (2001) Double-blind randomized control trial of the effect of recombinant human erythropoietin on chemotherapy-induced anemia in patients with non-small cell lung cancer. Int J Clin Oncol 6:296-301
16. ten Bokkel Huinink WW, de Swart CA, van Toorn DW et al (1998) Controlled multicentre study of the influence of subcutaneous recombinant human erythropoietin on anaemia and transfusion dependency in patients with ovarian carcinoma treated with platinum-based chemotherapy. Med Oncol 15:174-182
17. Crawford J, Robert F, Perry M et al (2003) Epoetin alfa 40,000 u once weekly maintains hemoglobin in advanced non-small-cell lung cancer patients receiving first-line chemotherapy (Abstract 2527). Proc Am Soc Clin Oncol 22:628
18. Thatcher N, De Campos ES, Bell DR et al (1999) Epoetin alpha prevents anaemia and reduces transfusion requirements in patients undergoing primarily platinum-based chemotherapy for small cell lung cancer. Br J Cancer 80:396-402
19. Del Mastro L, Venturini M, Lionetto R et al (1997) Randomized phase III trial evaluating the role of erythropoietin in the prevention of chemotherapy-induced anemia. J Clin Oncol 15:2715-2721
20. Henry DH, Brooks BJ Jr, Case DC Jr et al (1995) Recombinant human erythropoietin therapy for anemic cancer patients receiving cisplatin chemotherapy. Cancer J Sci Am 1:252
21. Bokemeyer C, Aapro MS, Courdi A et al (2004) EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer. Eur J Cancer 40:2201-2216
22. Cazzola M, Beguin Y, Kloczko J et al (2003) Once-weekly epoetin beta is highly effective in treating anaemic patients with lymphoproliferative malignancy and defective endogenous erythropoietin production. Br J Haematol 122:386-393
23. Leonard R, Aapro M, Chan S et al (2004) Once weekly epoetin beta in patients with metastatic breast cancer receiving anthracycline- or taxane-based chemotherapy. Ann Oncol 15(Suppl 3): (Abstract 188P)
24. Leyland-Jones B (2003) Breast cancer trial with erythroprotein terminated unexpectedly. Lancet Oncol 4:459-460
25. Henke M, Laszig R, Rube C et al (2003) Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 362:1255-1260
26. Aapro M et al (2004) Effect of epoetin beta on tumour progression and survival in patients with cancer: a meta-analysis of controlled clinical studies. Ann Oncol 15 (Suppl 3): (Abstract 841P)
27. Bohlius J, Langensiepen S, Schwarzer G et al (2005) Recombinant human erythropoietin and overall survival in cancer patients: results of a comprehensive meta-analysis. J Natl Cancer Inst 97:489-498
28. Coiffier B, Boogaerts M, Aapro M et al (2004) Thrombo-embolic events in patients with cancer treated with NeoRecormon® (epoetin beta): a meta-analysis of controlled trials. ESMO (Abstract)
29. Crawford J, Cella D, Cleeland CS et al (2002) Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. Cancer 95:888-895
30. Henry DH (2005) Epoetin alfa for the treatment of cancer-and chemotherapy-related anaemia: product review and update. Expert Opin Pharmacother 6:295-310
31. Barrett-Lee PJ, Ludwig H, Bokemeyer C et al (2003) Independent risk factors for anemia in cancer (CA) patients (pts) are defined by logistic regression modeling: results from the European Cancer Anaemia Survey (ECAS) (Abstract 2946). Proc Am Soc Clin Oncol 22:733